Pharmaceuticals

JLPC

JLPC released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 810.63 M, actual EPS CNY 0.02

JLPC to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

JLPC released FY2025 Annual Earnings on April 20 After-Market (BJT), actual revenue CNY 2.712 B, actual EPS CNY -0.34

JLPC released FY2025 Q4 earnings on April 20 After-Market (BJT), actual revenue CNY 629.4 M, actual EPS CNY -0.2257

JLPC to Release FY2025 Earnings on April 21 After-Market (BJT)

JLPC FY2025 Q3 Earnings Release on October 25, 2025, After-Market (BJT)

JLPC released FY2025 Q3 earnings on October 13 After-Market (BJT), actual revenue CNY 797.12 M, actual EPS CNY 0.0162

JLPC released FY2025 9 Months Earnings on October 13 After-Market (BJT), actual revenue CNY 2.082 B, actual EPS CNY -0.1261

JLPC released FY2025 Semi-Annual earnings on August 26 During-Market BJT, actual revenue CNY 1.285 B, actual EPS CNY -0.14

JLPC released FY2025 Q2 earnings on August 26 During-Market (BJT), actual revenue CNY 657.64 M, actual EPS CNY -0.2224

JLPC FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Xinxiang Changle Pharmaceutical's Lincomycin Hydrochloride Injection Passed Consistency Evaluation

Lianhuan Pharmaceutical Fined for Monopoly, Reports Losses

Lianhuan Pharmaceutical Plans to Issue Sci-Tech Innovation Bonds

Lianhuan Pharmaceutical Discloses 2025 H1 R&D Expense Forecast

Lianhuan Pharmaceutical's Felodipine Tablets Pass Consistency Evaluation

Policy Favoring Innovative Drugs Released, Hong Kong and A-Share Innovative Drug Sector Soars

Lianhuan Pharmaceutical and Subsidiary Plan to Invest 300 Million Yuan in New Cancer Treatment Plant

Collective Adjustment in Innovative Pharmaceutical Stocks

Lianhuan Pharmaceutical Announces Expected Net Loss for First Half of 2025

688302

600513

09992

Innovative drug concept stocks showed active performance, with JLPC touching the daily limit, Menovo hitting 5 daily limits in 6 days, and Kingchem, Hinova, SDKX, DEZHAN HEALTHCARE, and WBDE following suit. In morning trading, the military industry sector surged; Jianshe Industry hit 2 daily limits in 4 days, while North Long Dragon, GreatWall Military, Jieqiang Equipment, FIRMACO, and Guoke Group climbed

- On March 27, A-shares opened low but recovered slightly, with key indices reducing losses; various sectors like CRO and innovative pharmaceuticals showed strength, while memory and optical communication hardware adjusted.  
- The bond market saw a downturn, with government bond futures declining, and most domestic commodity futures also fell, particularly for indexes and certain metals.  
- Lithium battery material stocks remained strong, with significant production increases noted for energy storage cells, while innovative drug stocks and military sectors exhibited particular upward movements amidst geopolitical tensions affecting oil prices.

Wallstreetcn

Hinova

POP MART

Menovo

SDKX

DEZHAN HEALTHCARE

WBDE

North Long Dragon

Guoke Group

Jieqiang Equipment

Kingchem

FIRMACO

GreatWall Military

Shanghai Composite Nears Positive Territory, Pharmaceutical Stocks Surge, Computing Hardware Stocks Continue to Adjust, HSI Fluctuates Higher, New Consumption Concept Stocks Rebound, POP MART Rises 2%

300878

688221

688443

688091

The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit

WECOME

Froniter Biotechnologies

Genrix Bio

SHANGHAI YIZHONG

JLPC announced that its revenue for the third quarter was 797 million yuan, a year-on-year increase of 53.81%; net profit was 4.9662 million yuan, a year-on-year decrease of 83.34%. Revenue for the first three quarters was 2.082 billion yuan, a year-on-year increase of 26.63%; net profit was -35.0621 million yuan, a year-on-year decrease of 137.82%

Zhitong

JLPC: The net profit for the third quarter was 4.9662 million yuan, a year-on-year decrease of 83.34%

JLPC's wholly-owned subsidiary plans to purchase certain buildings and land use rights from a controlling subsidiary of its controlling shareholder for RMB 74.5 million. This transaction is a related party transaction and does not constitute a major asset restructuring. It has been approved by the board of directors and the board of supervisors, pending review by the shareholders' meeting and relevant approval procedures. The purpose of this transaction is to optimize resource allocation, expand asset scale, and enhance overall strength

JLPC: Wholly-owned subsidiary plans to purchase assets, transaction price is 74.5 million yuan

On September 10th, Chengdu Yazhong Biopharmaceutical Co., Ltd. signed a deep strategic cooperation agreement with Yangzhou Lianhuan Investment Co., Ltd. and Nanjing Lianzhi Pharmaceutical Technology Co., Ltd. As subsidiaries of Lianhuan Pharmaceutical, Yazhong Pharmaceutical, Lianhuan Investment, and Nanjing Lianzhi will jointly establish a project team to fully promote the early market launch and transformation of R&D products; at the same time, through deep integration of the upstream and downstream of the industrial chain, further enhance Lianhuan Pharmaceutical's core competitiveness in the field of cardiovascular treatment

JLPC's subsidiaries sign strategic cooperation agreements

JLPC recently obtained the "Drug Registration Certificate" for Famotidine Injection approved by the National Medical Products Administration. This medication treats by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists. The acquisition of this certificate enriches the company's product line and enhances market competitiveness, but it is expected to have no significant impact on recent operating performance

JLPC has obtained the drug registration certificate for Famotidine Injection

According to the Zhitong Finance APP, JLPC announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. (referred to as "Changle Pharmaceutical"), recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, for the drug named Amlodipine Besylate Tablets. Amlodipine Besylate Tablets are a commonly used medication for regulating vascular pressure

JLPC: Benzenesulfonic Acid Amlodipine Tablets Complete Drug Registration

002536

002298

In the afternoon, high-priced stocks continued to decline, with JLPC, ZDXL, FLAC, and Jintian shares hitting the limit down, while Shenlian Bio, Sino Medical, Jiming Health, Wolong Electric Drive, Chuanrun Shares, Hanzhong Precision Machinery, and Guangshengtang all fell over 8%

FLAC

ZDXL

High-priced stocks continued to decline in the afternoon, with multiple stocks including JLPC hitting the limit down

002826

003020

600521

601089

603811

The chemical pharmaceutical sector fluctuated and weakened, with TIBET AIM PHARM hitting the limit down, followed by Lifeon Pharmaceutical, JLPC, huahaipharm, Foyou Pharma, and CHENGYIPHARMA

TIBET AIM PHARM

Lifeon Pharmaceutical

huahaipharm

Foyou Pharma

CHENGYIPHARMA

JLPC announced that its wholly-owned subsidiary recently passed the GMP compliance inspection for the oral solution production line No. 1. The inspection was conducted by the Anhui Provincial Drug Administration from June 4 to June 7, 2025, focusing mainly on the production of Ebastine oral solution. The investment in the production line was approximately 7.5 million yuan

JLPC: The newly built oral solution production line No. 1 has passed the drug GMP compliance inspection for the first time

JLPC(600513.SH)